A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ? / CORRADO TARELLA; MARCO LADETTO; FABIO BENEDETTI; UMBERTO VITOLO; ALESSANDRO PULSONI; CATERINA PATTI; VINCENZO CALLEA; ALESSANDRO RAMBALDI; ANDREA PICCIN; MICHELE MAGNI; MAURIZIO MUSSO; EMILIO IANNITTO; PIERANGELO SPEDINI; ANNA MARINA LIBERATI; FABIO CICERI; ANDREA GALLAMINI; FRANCESCO RODEGHIERO; GUIDO GINI; ALBERTO DE CRESCENZO; DI RAIMONDO F; ALESSANDRO LEVIS; TEODORO CHISESI; TOMMASINA PERRONE; DELIA ROTA SCALABRINI; GIUSEPPE ROSSI; ANGELO MICHELE CARELLA; GUIDO PARVIS; IGNAZIO MAJOLINO; ROBERTO PASSERA; MARCO RUELLA; ALESSANDRO PILERI; ALESSANDRO GIANNI; AND PAOLO CORRADINI. - 114(2009), pp. 882-882.
Titolo: | A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ? |
Autori interni: | |
Data di pubblicazione: | 2009 |
Handle: | http://hdl.handle.net/20.500.11769/75944 |
Appare nelle tipologie: | 4.1 Contributo in Atti di convegno |